Aims: Benefits of long acting beta 2 agonists are unclear for severe chronic obstructive pulmonary disease (COPD) patients with poor response to short acting bronchodilators. We aimed to evaluate 1) effects of eformoterol in such patients using a ‘n-of-1’ double crossover study design, and 2) aggregate data as a double-blind, double crossover randomized control trial. Methods: Subjects with forced expiratory volume in one second (FEV1) < 60% predicted, and poor response to short acting bronchodilators were studied six times over 18 weeks. During that time they were prescribed four weeks of either eformoterol or placebo, followed by the alternate, and then a second crossover. Four-weekly measures included six minute walk distance (6MWD), FEV1, previous two weeks of symptoms, and chronic respiratory questionnaire (CRQ) including treatment goal items. Results: Of 27 original subjects (21 male, mean age of 70 years, five smokers, mean prebronchodilator FEV1, 36% predicted), one subject had clinically significant concordant improvement in the CRQ dyspnoea domain and 6MWD (by 51 metres), but not for other outcomes. There were no concordant improvements in any other subjects. Aggregate double crossover data analysis demonstrated no improvement in any outcome measures. Conclusions: The ‘n-of-1’ study design and aggregate data analysis demonstrated lack of benefit from eformoterol in COPD patients with poor response to short acting bronchodilators.
1. Cydulka R , McFadden ER Jr , Emerman C , Sivinski L , Pisanelli W , Rimm A . Patterns of hospitalization in elderly patients with asthma and chronic obstructive pulmonary disease . Am J Resp Crit Care Med1997; 156: 1807-1812 .
2.
2. Burdon J , Edwards R . The chronic obstructive pulmonary disease strategy . Intern Med J2002; 32: 64-65 .
3.
3. Australian Institute of Health and Welfare (AIHW) . Australia's Health 2000: the seventh biennial health report of the AIHW. Canberra, Australia: Commonwealth of Australia , 2000.
4.
4. National Heart Lung and Blood Institute , World Health Organisation . Workshop report: global strategy for the diagnosis, management of prevention of COPD. National Institutes of Health, Bethesda, USA , 2001.
5.
5. Jones D , Peters T . Caring for elderly dependents: effects on the carer's quality of life . Age Aging1992; 21: 421-428 .
6.
6. Appleton S , Poole P , Smith B , Veale A , Bara A . Long-acting beta2-agonists for chronic obstructive pulmonary disease patients with poorly reversible airflow limitation . Cochrane Database Sys Rev2002; 3: CD001104-CD001104 , http://www.cochranelibrary.com.
7.
7. Grove A , Lipworth B , Reid P et al. Effects of regular salmeterol on lung function and exercise capacity in patients with chronic obstructive airways disease . Thorax1996; 51: 689-693 .
8.
8. Boyd G , Morice A , Pounsford J , Siebert M , Peslis N , Crawford C . An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD) . Eur Respir J1997; 10: 815-821 .
9.
9. Ulrik C . Efficacy of inhaled salmeterol in the management of smokers with chronic obstructive pulmonary disease: a single centre randomised, double blind, placebo controlled, crossover study . Thorax1995; 50: 750-754 .
10.
10. Jones PW , Bosh TK . Quality of life changes in COPD patients treated with salmeterol . Am J Respir Crit Care Med1997; 155: 1283-1289 .
11.
11. Mahler D , Donohue J , Barbee R et al. Efficacy of salmeterol xinafoate in the treatment of COPD . Chest1999; 115: 957-965 .
12.
12. Stahl E , Wadbo M , Bengtsson T et al. Health-related quality of life, symptoms, exercise capacity and lung function during treatment for moderate to severe COPD . J Drug Assess2002; 5: 81-94 .
13.
13. Rossi A , Kristufek P , Levine B et al. Comparison of the efficacy, tolerability and safety of eformoterol dry powder and oral slow-release theophylline in the treatment of COPD . Chest2002; 12: 1058-1069 .
14.
14. Rutten-van Molken M , Roos B , van Noord J . An empirical comparison of the St George's Respiratory Questionnaire (SGRQ) and the Chronic Respiratory Disease Questionnaire (CRQ) in a clinical setting . Thorax1999; 54: 995-1003 .
15.
15. Guyatt GH , Berman LB , Townsend M et al. A measure of quality of life for clinical trials in chronic lung disease . Thorax1987; 42: 773-778 .
16.
16. Patel A , Jaeschke R , Guyatt GH , Keller JL , Newhouse MT . Clinical usefulness of n-of-1 randomised controlled trials in patients with nonreversible chronic airflow limitation . Am Rev Respir Dis1991; 144: 962-964 .
17.
17. Redelmeier D , Guyatt G , Goldstein R . Assessing the minimal important difference in symptoms: a comparison of two techniques . J Clin Epidemiol1996; 49: 1215-1219 .
18.
18. British Thoracic Society . BTS guidelines for the management of chronic obstructive pulmonary disease. The COPD Guidelines Group of the Standards of Care Committee of the BTS . Thorax1997; 52: S1-S28 .
19.
19. Guyatt G , Sackett D , Taylor D , Chong J , Roberts R , Pugsley S . Determining optimal therapy - randomised trials in individual patients . N Eng J Med1986; 314: 889-892 .
20.
20. American Thoracic Society . Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease . Am J Respir Crit Care Med1995; 152: S77-S121 .
21.
21. Senn S . Cross over trials in clinical research. Chichester, UK: John Wiley and Sons , 1993.
22.
22. Jones B , Kenward MG . Design and analysis of cross-over trials. London, New York: Chapman & Hall , 1989.
23.
23. Stata Statistical Software StataCorp, Version 6.0. College Station, Texas.
24.
24. Siafakis N , Vermiere P , Pride N et al. The optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force . Eur Respir J1995; 8: 1398-1420 .
25.
25. Cazzola M , Matera M . Should long-acting beta 2-agonists be considered an alternative first choice option for the treatment of stable COPD?Respir Med1999; 93: 227-229 .
26.
26. Cazzola M , Santangelo G , Piccolo A et al. Effect of salmeterol and formoterol in patients with chronic obstructive pulmonary disease . Pulm Pharmacol1994; 7: 103-107 .
27.
27. Thomson N , Angus R , Quebec-Fehling E , Brambilla R . Efficacy and tolerability of formoterol in elderly patients with reversible obstructive airways disease . Respir Med1998; 92: 562-567 .
28.
28. Jones P . Health status measurement in chronic obstructive pulmonary disease . Thorax2001; 56: 880-887 .
29.
29. O'Donnell D , Lam M , Webb K . Measurement of symptoms, lung hyperinflation, and endurance during exercise in chronic obstruc-tive pulmonary disease . Am J Respir Crit Care Med1998; 158: 1557-1565 .
30.
30. Aalbers R , Ayres J , Backer V et al. Formoterol in patients with chronic obstructive pulmonary disease: a randomized, controlled, 3-month trial . Eur Respir J2002; 19: 936-943 .
31.
31. Dewar M , Jamieson A , McLean A , Crompton GK . Peak inspiratory flow through Turbuhaler in chronic obstructive airways disease . Respir Med1999; 93: 342-344 .
32.
32. Brand P , Quanjer P , Postma D et al. Interpretation of bronchodilator response in patients with obstructive airways disease. The Dutch Chronic Non-Specific Lung Disease (CNSLD) Study Group . Thorax1992; 47: 429-436 .
33.
33. Dompeling E , Van Schayck C , Molema J et al. A comparison of six different ways of expressing the bronchodilating response in asthma and COPD; reproducibility and dependence of pre-bronchodilator FEV1 . Eur Respir J1992; 5: 975-981 .
34.
34. Anthonisen N , Wright E , Hodgkin J . Prognosis in chronic obstructive pulmonary disease . Am Rev Respir Dis1986; 133: 14-20 .
